Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

NuvaRing Lawsuit Alleges 22-year-old Woman Developed Life-Threatening Blood Clot Disorders Due to NuvaRing, Filed by Wright & Schulte
  • USA - English


News provided by

Wright & Schulte LLC

Dec 03, 2013, 14:15 ET

Share this article

Share toX

Share this article

Share toX

If you or someone you love suffered a blood clot, pulmonary embolism, deep vein thrombosis, heart attack, stroke or sudden death while using NuvaRing, visit yourlegalhelp.com, or call  1-800-399-0795
If you or someone you love suffered a blood clot, pulmonary embolism, deep vein thrombosis, heart attack, stroke or sudden death while using NuvaRing, visit yourlegalhelp.com, or call 1-800-399-0795

Columbus, OH (PRWEB) December 03, 2013 -- Wright & Schulte has recently filed a NuvaRing lawsuit on behalf of a 22-year-old woman from Dayton, Ohio who allegedly developed life threatening blood clots due to her use of the birth control NuvaRing. This lawsuit (Case No. 3:13-cv-00328-WHR) was filed on September 24, 2013 in the U.S. District Court of Ohio. It contends that the defendants, Organon USA, Inc. and Merck & Co., Inc., marketed NuvaRing as a safe and effective form of contraception, despite knowing about the serious side effects linked to it.

If you or someone you love suffered a blood clot, pulmonary embolism, deep vein thrombosis, heart attack, stroke or sudden death while using NuvaRing, visit yourlegalhelp.com, or call 1-800-399-0795

Post this

The NurvaRing lawsuit, filed by Wright & Schulte LLC, states that the plaintiff started using NuvaRing in March or April 2012. On April 22, 2012, the plaintiff reportedly experienced severe chest pain and shortness of breath. These symptoms caused her to go to the hospital, where she submitted to a CT scan. Following this scan, medical professionals told the plaintiff that she had developed massive bilateral emboli (blood clots) in her lungs, as well as deep vein thrombosis in her right leg. To treat these life-threatening complications, the plaintiff was hospitalized for 15 days and was placed on anticoagulation therapy, including Coumadin, Fragmin and Lovenox. In the aftermath of her hospitalization, the plaintiff has had to continue anticoagulation therapy and attend regular follow-up doctor’s appointments to monitor her health.

Negligence alleged in NuvaRing Lawsuit:
This NuvaRing blood clot lawsuit contends that, while the plaintiff’s use of NuvaRing caused her to develop life-threatening injuries, Organon and the other defendants knew about the substantial risks of such side effects and, nevertheless, failed to warn the public about them. In fact, according to court documents, this NuvaRing lawsuit alleges that the defendants purported the safety and effectiveness of NuvaRing and failed to warn women about the serious risks of deep vein thrombosis and pulmonary embolism associated with NuvaRing use.

The complaint further contends that this case should be transferred to the federal NuvaRing multidistrict litigation (MDL) currently underway in U.S. District Court, Eastern District of Missouri. Currently, there are more than 1,500 NuvaRing blood clot lawsuits pending in the Missouri MDL. The first bellwether case in this litigation has been set to get underway in April 2014, according to an Order dated October 8, 2013. In this Order, Judge Rodney W. Sippel, who is overseeing the federal NuvaRing litigation, directed that all discovery, motions and rulings be stayed in the federal NuvaRing lawsuits until December 2013. Judge Sippel also mandated that the plaintiffs’ lawyers conduct a census “of all claims they are pursuing, whether they are pending in federal court, state court or have not yet been filed.” According to the Order, the information sought by the Court must be presented by October 28, 2013. (In re NuvaRing Products Liability Litigation, MDL 1964)

For further information on this and other NuvaRing lawsuits visit our website.

Wright & Schulte, LLC focuses on defending the rights of those who have sustained serious injuries after using dangerous medications and defective medical devices. Our skilled NuvaRing attorneys are experienced at successfully defending the rights of those who have been injured. We encourage those who believe that they have been injured due to the use of NuvaRing to speak with our knowledgeable and experienced NuvaRing lawyers by visiting yourlegalhelp.com or by calling 1-800-399-0795.

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure their rights. You deserve a law firm that will guarantee the aggressive and personal representation you deserve, contact Wright & Schulte LLC today. Free NuvaRing Lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
"An Experienced Harmful Drug Law Firm"
1-800-399-0795
http://www.yourlegalhelp.com

Richard Schulte, Wright & Schulte LLC, http://www.yourlegalhelp.com, +1 1-800-399-0795, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.